Top Markets
#1 Black Phoenix Black Phoenix +861.09%
#2 Nesa Nesa +437.04%
#3 QuantixAI QuantixAI +114.07%
#4 MetaDAO MetaDAO +31.49%
#5 Ontology Gas Ontology Gas +26.44%
#6 Bedrock Bedrock +19.41%
#7 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +16.86%
#8 Stacks Stacks +14.78%
#9 Prom Prom +14.13%
#10 Pons Pons +13.40%
Coin of the day
Black Phoenix Black Phoenix
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

6990
Classificação em ações #1490
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company,... Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Preço da ação
$66.97
Valor de mercado
$15.62B
Variação (1 dia)
0.10%
Variação (1 ano)
11.36%
País
CN
Negociar Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990)

Categoria

Healthcare
Receita da Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH